Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early ...
AC Immune First Half 2026 Financial and Corporate UpdateFocused portfolio of wholly-owned programs approach near-term clinical catalysts as ...
Add Yahoo as a preferred source to see more of our stories on Google. Quilceda Creek specialzies in 100% estate grown ...
Interest income.Interest income was $31.5 million and $51.3 million for the three months ended June 30, 2026 and 2025, respectively. The decrease in interest income was primarily due to a decrease in ...
OpenAI education plugins move AI from single answers to multi-step workflows. The valuable skill becomes directing the ...
Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on ...
The launch of specialized investment funds (SIFs) with favourable tax structures and lower entry barriers has disrupted India ...
Pipeline continues to advance, including the RAP-219 long-acting injectable and primary generalized tonic-clonic seizures program, and the RAP-641 a6ß4 nAChR program in chronic pain and migraine Ended ...
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the quarter ended June 30, 2026, and provided a ...
Marpai, Inc. (OTCQX: MRAI) is a healthcare technology company providing Third-Party Administration and Pharmacy Benefit Management services. The Company supports self-funded employer health plans with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results